enGene Holdings Inc.
ENGN
NASDAQ·Healthcare·Biotechnology·Mkt cap $124.3M
$1.89
▲ +1.89%
P/E
-1.43
Mkt Cap
$124.3M
52-Wk Range
$1.40–$12.25
52-Week Range
$1.40 - $12.25
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 61.4% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary non-viral delivery technology
- First-to-market potential in BCG-refractory bladder cancer
- Unique mucosal tissue targeting capabilities
- Unmet medical need in oncology space
Bear Case
1 risk
- Low volatility (beta -0.3).
Growth
Stable outlook
Clinical trial progression and regulatory approval of EG-70
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Strong
+6.6% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying ENGN right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Sep 14, 2026
JUN 15, 2026
Reported EPS of -$0.43 vs -$0.48 consensus (+10.4% surprise).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q2 26
+10.4%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
8 analysts · 25% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
25%
Hold
63%
Sell
13%
Median Price Target
—
Latest: Morgan Stanley · Jun 18, 2026
vs Industry
How ENGN stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related